Minireviews
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Jul 24, 2021; 12(7): 557-564
Published online Jul 24, 2021. doi: 10.5306/wjco.v12.i7.557
Esophagogastric junction adenocarcinoma: Preoperative chemoradiation or perioperative chemotherapy?
Francisco Laxague, Francisco Schlottmann
Francisco Laxague, Francisco Schlottmann, Department of Surgery, Hospital Alemán of Buenos Aires, Buenos Aires 1118, Argentina
Francisco Schlottmann, Division of Esophageal and Gastric Surgery, Hospital Alemán of Buenos Aires, Buenos Aires 1118, Argentina
Author contributions: Laxague F contributed to conception and design, acquisition of data, drafting of the article and final approval of the version to be published; Schlottmann F contributed to conception and design, acquisition of data, drafting of the article and final approval of the version to be published.
Conflict-of-interest statement: There is no conflict of interest associated with any of the authors that contributed efforts in this manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Francisco Schlottmann, MD, Surgeon, Department of Surgery, Hospital Alemán of Buenos Aires, Av. Pueyrredón 1640, Buenos Aires 1118, Argentina. fschlottmann@hotmail.com
Received: February 25, 2021
Peer-review started: February 25, 2021
First decision: May 4, 2021
Revised: May 10, 2021
Accepted: June 25, 2021
Article in press: June 25, 2021
Published online: July 24, 2021
Core Tip

Core Tip: Surgical treatment only has shown poor results in patients with locally advanced esophagogastric junction tumors. Perioperative chemotherapy and neoadjuvant chemoradiation are valid treatment modalities for these patients. This evidence-based review explores the results, advantages, and disadvantages of both approaches. In addition, future directions with potentially effective novel drugs are also discussed.